Tracon discontinues CD105 mAb carotuximab

Tracon discontinued development of carotuximab (TRC105) following an interim futility analysis of the Phase III TAPPAS trial to treat advanced or metastatic angiosarcoma.

Tracon Pharmaceuticals Inc. (NASDAQ:TCON) said an analysis of more than 120 patients in TAPPAS showed that carotuximab plus Votrient pazopanib did not show "clinically meaningful efficacy," and that an IDMC recommended the trial be discontinued...